For research use only. Not for therapeutic Use.
(-)-Epigallocatechin（Cat No.:I005708）is a naturally occurring catechin, primarily found in green tea, known for its potent antioxidant, anti-inflammatory, and anti-cancer properties. It works by scavenging free radicals and inhibiting oxidative stress, contributing to cellular protection. Additionally, (-)-Epigallocatechin has been shown to modulate various signaling pathways, including those involved in inflammation, apoptosis, and metabolism, making it of interest in research related to cardiovascular diseases, cancer, and neuroprotection. Its broad therapeutic potential, especially in promoting heart and brain health, has made it a key compound in nutraceutical and pharmaceutical studies.
| Catalog Number | I005708 |
| CAS Number | 970-74-1 |
| Synonyms | (2R,3R)-2-(3,4,5-trihydroxyphenyl)chroman-3,5,7-triol |
| Molecular Formula | C15H14O7 |
| Purity | ≥95% |
| Target | PKC |
| Solubility | 10 mM in water |
| Storage | Store at -20°C |
| IUPAC Name | (2R,3R)-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromene-3,5,7-triol |
| InChI | InChI=1S/C15H14O7/c16-7-3-9(17)8-5-12(20)15(22-13(8)4-7)6-1-10(18)14(21)11(19)2-6/h1-4,12,15-21H,5H2/t12-,15-/m1/s1 |
| InChIKey | XMOCLSLCDHWDHP-IUODEOHRSA-N |
| SMILES | C1[C@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)O |
| Reference | </br>1:Morphometric abnormalities in the spleen of the progeny of mice fed epigallocatechin during gestation and nursing. Bałan BJ, Skopińska-Różewska E, Skopiński P, Zdanowski R, Leśniak M, Kiepura A, Lewicki S.Pol J Vet Sci. 2017 Mar 28;20(1):5-12. doi: 10.1515/pjvs-2017-0001. PMID: 28525335 </br>2:(-)-Epigallocatechin-3-gallate ameliorates memory impairment and rescues the abnormal synaptic protein levels in the frontal cortex and hippocampus in a mouse model of Alzheimer/’s disease. Guo Y, Zhao Y, Nan Y, Wang X, Chen Y, Wang S.Neuroreport. 2017 May 17. doi: 10.1097/WNR.0000000000000803. [Epub ahead of print] PMID: 28520620 </br>3:Bioinformatics Analysis on Molecular Mechanism of Green tea Compound Epigallocatechin-3-Gallate Against Ovarian Cancer. Xinqiang S, Mu Z, Lei C, Mun LY.Clin Transl Sci. 2017 May 15. doi: 10.1111/cts.12470. [Epub ahead of print] PMID: 28504421 </br>4:Comparison of the impact of epigallocatechin gallate and ellagic acid in an experimental cataract model induced by sodium selenite. Ergen I, Turgut B, Ilhan N.Int J Ophthalmol. 2017 Apr 18;10(4):499-506. doi: 10.18240/ijo.2017.04.01. eCollection 2017. PMID: 28503419 Free PMC Article</br>5:Epigallocatechin gallate has pleiotropic effects on transmembrane signaling by altering the embedding of transmembrane domains. Ye F, Yang C, Kim J, MacNevin CJ, Hahn KM, Park D, Ginsberg MH, Kim C.J Biol Chem. 2017 May 9. pii: jbc.C117.787309. doi: 10.1074/jbc.C117.787309. [Epub ahead of print] PMID: 28487468 Free Article</br>6:Effect of epigallocatechin-3-gallate on the increase in type II collagen accumulation in cartilage-like MSC sheets. Sato K, Mera H, Wakitani S, Takagi M.Biosci Biotechnol Biochem. 2017 Jun;81(6):1241-1245. doi: 10.1080/09168451.2017.1282809. Epub 2017 Feb 28. PMID: 28485205 </br>7:Epigallocatechin gallate inhibits the growth of salivary adenoid cystic carcinoma cells via the EGFR/Erk signal transduction pathway and the mitochondria apoptosis pathway. Weng LX, Wang GH, Yao H, Yu MF, Lin J.Neoplasma. 2017 May 9;64. doi: 10.4149/neo_2017_410. [Epub ahead of print] PMID: 28485162 </br>8:Epigallocatechin-3-gallate counters cisplatin toxicity of rat testes. Fouad AA, Qutub HO, Fouad AEA, Audeh AM, Al-Melhim WN.Pharm Biol. 2017 Dec;55(1):1710-1714. doi: 10.1080/13880209.2017.1322618. PMID: 28478745 </br>9:Epigallocatechin-3-gallate ameliorates hypoxia-induced pulmonary vascular remodeling by promoting mitofusin-2-mediated mitochondrial fusion. Zhu TT, Zhang WF, Luo P, He F, Ge XY, Zhang Z, Hu CP.Eur J Pharmacol. 2017 May 3. pii: S0014-2999(17)30306-0. doi: 10.1016/j.ejphar.2017.05.003. [Epub ahead of print] PMID: 28478070 </br>10:Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes. Stringer M, Abeysekera I, Thomas J, LaCombe J, Stancombe K, Stewart RJ, Dria KJ, Wallace JM, Goodlett CR, Roper RJ.Physiol Behav. 2017 May 3;177:230-241. doi: 10.1016/j.physbeh.2017.05.003. [Epub ahead of print] PMID: 28478033 |
